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Abstract 
Thioguanine derivatives, azathioprine and 6-mercaptopurine, represent major drugs in the treatment of chronic 
active inflammatory bowel disease. They are effective in two-thirds of the patients and safe over the long term in 
patients who can tolerate them (80-90%). Recent progress in understanding the metabolism of these drugs and its 
implication in clinical practice have brought up new tools and strategies that are proposed to optimize treatment. 
In particular, the measurement and characterization of key enzymes and metabolites may have clinical impact. 
Thus, thiopurine methyl transferase genotyping and activity measurement, as well as erythrocytes, 6-thioguanine 
nucleotides and 6-methyl mercaptopurine levels, may help in some situations of intolerance or inefficacy with 
these drugs. Indications for starting and stopping treatment with thioguanine derivatives are also discussed. 
Keywords : Crohn's disease ; ulcerative colitis ; inflammatory bowel disease ; azathioprine ; 6-mercaptopurine ; 
6-thioguanine nucleotides ; thiopurine methyl transferase. 
 
Thioguanine derivatives, essentially azathioprine (AZA) and 6-mercaptopurine (6-MP), have been used for 
decades in the treatment of inflammatory bowel disease (IBD). They are considered to be major drugs in the 
treatment of steroid-dependent and chronic active IBD. A meta-analysis clearly showed that their efficacy in 
Crohn's disease (CD) correlates with the cumulative dose administered, depending on the dose and duration of 
treatment.1 At a dosage of 1.0-1.5 mg/kg of 6-MP and 2.0-2.5 mg/kg of AZA, one can expect two-thirds to three-
quarters of the patients to respond after 3-4 months of treatment.2-5 More recently AZA and 6-MP have also 
proved to be useful as maintenance treatment in patients treated with infliximab, probably increasing the 
response rate6 and diminishing the risk of infusion reactions.7 Fewer data have been published in ulcerative 
colitis (UC), but available controlled data8-10, as well as reference centre experience5,11 indicate similar efficacy. 
Tolerance and safety over the short and the long term have also been shown to be reasonably good. Two types of 
adverse reactions can occur in 15-25% of the patients5,12-14: allergic type and non-allergic type. 
The first type usually occurs within the first 3-4 weeks of treatment and is not dose-dependent. It includes 
pancreatitis (3%), fever, rash, malaise (2%), digestive intolerance (10%) and some cases of hepatitis (0.3-3%). 
The second type usually occurs later, at any time, is dose-dependent and includes bone marrow depression (2-
5%), infections (2.5-7.5%), malignancies (3-5%) and some cases of hepatitis. Importantly, the relative risk of 
malignancy does not seem to be increased even with long-term treatment.14 An association of good efficacy and 
good tolerance may translate into improved quality of life. This has been shown with AZA/6-MP in 
inflammatory bowel disease.15 In this study, the immunosuppressive treatment (which was mainly AZA) was the 
main factor improving quality of life. 
Despite this rather good profile, improvement can always be sought. Optimize treatment with these drugs 
includes better defining indication and place in therapeutic strategies of IBD, accelerating and increasing 
efficacy, improving tolerance and safety. To achieve these aims, our understanding of the metabolism, 
biochemistry and pharmacogenetics of thioguanine derivatives must be improved. Thanks to recent progress in 
these fields, several tools are now available and new strategies are proposed, which we are going to develop. For 
practical and didactic reasons, these will be developed in an order corresponding to the phases of treatment, 
starting with the initiation of treatment, the early phase, mid- and long-term treatment, and finally the decision to 
stop treatment. For these periods, available tools and proposed strategies will be discussed, referring when 
possible to the metabolism of these drugs. 
METABOLISM OF THIOGUANINE DERIVATIVES (Figure I) 
Among thioguanine derivatives, three compounds can be used for the treatment of IBD: AZA (Figure I, no. I) 
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and 6-MP (Figure I, no. 2), which are the most commonly used drugs, and also 6-thioguanine (6-TG) (Figure I, 
no. 3), which is used mainly by haematologists in acute lymphoblastic leukaemia in children. Actually, AZA is 
quickly transformed into 6-MP by a non-enzymatic reaction using glutathione (Figure I, no. 4) or other 
sulfhydryl-containing proteins with the production of a nitro-imidazole derivative (Figure I, no. 13) that may 
have some immunomodulatory properties.16 6-MP (Figure I, no. 2) is then itself metabolized through three 
competitive enzymatic pathways mediated by xanthine oxidase (Figure I, no. 7), thiopurinemethyltransferase 
(TPMT) (Figure I, no. 5) or hypoxanthine guanine phosphoribosyl transferase (HGPRT) (Figure I, no. 6). The 
pathway of xanthine oxidase (XO) (Figure I, no. 7) leads to a presumed inactive metabolite, 6-thiouric acid (6-
TUA) (Figure I, no. 14), and can be inhibited by allopurinol (Figure I, no. 17). The XO gene does not seem to be 
polymorphic but 2% of the general population may have a deficient gene giving rise to hypouricaemia. The 
pathway of TPMT (Figure I, no. 5) leads to 6-methylmercaρtopurine (6-MMP) (Figure I, no. 15). The TPMT 
gene is polymorphic in the general population, with high- and low-metabolizing alleles, generating three 
possibilities for the rate of metabolism of 6-MP: two high-metabolizing alleles inducing a high-metabolizing 
pathway (88.6% of the population), one high- and one low-metabolizing allele, inducing an intermediate-
metabolizing pathway (11.1% of the population) and two low-metabolizing alleles, inducing a low-metabolizing 
pathway (0.3% of the population).17 TPMT activity can also be influenced by exogenous factors, including other 
drugs, such as diuretics, and AZA itself, that can induce TPMT activity (Figure I, no. 18) while sulfasalazine and 
mesalamine may have an inhibitory effect (Figure I, no. 19).I8 6-MMP (Figure I, no. 15) is thought to be inactive 
but seems to mediate some side-effects, including hepatotoxicity.19,20 The HGPRT pathway (Figure I, no. 6) 
leads to 6-thioinosine monophosphate (6-TIMP) (Figure 1, no. 9), 6-thioxanthosine monophosphate (6-TXMP) 
(Figure I, no. 10) and finally 6-thioguanine nucleotides (6-TGN) (Figure I, no. 11 and no. 12) which are thought 
to be the main active products of thioguanine derivatives. The mechanism of action of 6-TGN is still a matter of 
debate but its incorporation into DNA might trigger cell apoptosis and seems to be essential for cytotoxicity in 
leukaemia-derived cell lines. There is no polymorphism documented in the HGPRT gene but the Lesch Nyhan 
syndrome is characterized by a constitutive lack of activity of HGPRT. 6-TIMP (Figure I, no. 9) can also be 
metabolized by TPMT, producing methylated derivatives (MeTIMP) (Figure I, no. 16) that have a potential 
functional significance because they are inhibitors of phosphoribosylpyrophosphate amidotransferase (PPRP-
AT) (Figure I, no. 8), an enzyme involved in de novo purine synthesis.21 6-TG (Figure I, no. 3) is metabolized 
mainly by HGPRT, giving rise to 6-TGN. It thus represents the most direct pathway to 6-TGN production. 
NEW TOOLS AND STRATEGIES PROPOSED TO OPTIMIZE TREATMENT WITH THIOGUANINE 
DERIVATIVES 
These tools and strategies are the result of a better knowledge of the metabolism of thioguanine derivatives 
(Figure I). They can be used at various times during treatment with these drugs, from the initiation of treatment 
to the decision to stop it. 
Initiation of treatment 
When treatment is initiated several points must be discussed: the indication for treatment, the starting dose, the 
route of administration, TPMT genotyping and the measurement of TPMT activity, and the choice between AZA 
and 6-MP. Very few data are available to discuss this last point. The initial choice between AZA or 6-MP is 
thought to be equivalent and the preferential use of one of these by reference teams has probably been linked to 
tradition with, for example, a more frequent use of 6-MP in the USA and AZA in Europe. It may still be a 
question of debate, however, because the nitro-imidazole metabolite (Figure I, no. 13) released from AZA may 
theoretically induce side-effects22 but could also have some immunomodulatory effects participating in the 
efficacy of the drug.16,23 Indication, starting dose and route of administration on the one hand and TPMT 
genotyping and measurement of activity on the other hand are potentially linked aspects. 
Indication, starting dose and route of administration of thioguanine derivatives 
AZA and 6-MP are largely considered to be second- or even third-line treatments in IBD. However, these 
molecules have been shown to be able to induce deep and prolonged mucosal healing24 and could therefore 
change the natural history of the disease. Some recent studies have tried to evaluate the benefit of an earlier 
induction of AZA or 6-MP treatment. In CD, the adjunction of 6-MP to steroids to treat active disease in children 
within 8 weeks of diagnosis was shown to be beneficial in a placebo-controlled study.25 Induced remission rates 
were similar in the two arms but co-treatment with 6-MP 1.5 mg/kg/day was associated with a lower relapse rate 
over 18 months (9 versus 47%). Two remarks have to be made here: first, these impressive results need to be 
confirmed in adults, and second, there are no sufficient data today to support the systematic use of A2A or 6-MP 
in every patient with CD. An important task would be to try and define at-risk populations who would benefit 
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most from such early treatment.26 The use of AZA or 6-MP in active IBD has been hampered by slow action. An 
intravenous loading dose has been tried in order to reduce time to efficacy and also to extend the indication to 
severe active refractory disease. Preliminary results from small pilot studies were encouraging both in refractory 
CD27 and in severe refractory UC.28 However, a large controlled trial in CD has not confirmed the superiority of 
an intravenous loading dose of AZA over optimal oral dosage.29 In this last trial, however, the onset of action for 
oral AZA was quicker than previously admitted. Patients received 2 mg/kg/day of AZA and response to 
treatment appeared after 2 weeks and reached a plateau after 4 weeks. Furthermore, steady-state concentration of 
active metabolites 6-TGN (Figure I, no. 11 and no. 12) was reached after 2-3 weeks. In comparison, a treatment 
starting with an intermediate dose of AZA, such as 1 mg/kg, progressively increased to optimal dosage, may be 
associated with a slower onset of action. Such a progressive increase in dosage is used mainly for safety reasons 
but does not seem currently evidence-based. 
 
Figure I: Metabolism of thioguanine derivatives (for details, see text). The drugs that can be used in IBD are azathioprine 
(AZA) (I), 6-mercaptopurine (6-MP) (2) and 6-thioguanine (6-TG) (3). Key enzymes involved in the metabolism of these drugs are: 
thiopurine methyl transferase (TPMT) (5), hypoxanthine guanine phosphoribosyl transferase (HGPRT) (6) and xanthine oxidase (XO) (7). 
Active metabolites are 6-thioguanipie nucleotides (6-TGN) (11): 6-thioguanine mono-di-and triphosphate (6-TGMP, 6-TGDP, 6-TGTP) (12), 
which incorporate into DNA and RNA, and 6-methyl thioinosinic monophosphate (6-MeTIMP), which can interfere with de novo purine 
synthesis. Potentially toxic metabolites are 6-TGN (II), which can induce myelosuppression, and 6-methyl mercaptopurine (6-MMP) (15), 
which is probably involved in hepatotoxicity. 
 
 
TPMT genotyping and measurement of activity 
The rationale for TPMT genotyping or for TPMT activity measurement is, as mentioned above, that the activity 
of this enzyme is genetically determined and has a trimodal distribution, with intermediate- and, above all, low-
metabolizers being at risk of developing myelotoxicity due to preferential metabolism through HGPRT (Figure I, 
no. 6) and high production of 6-TGN metabolites (Figure I, no. 11 and no. 12). From a safety point of view it 
would seem wise to test before treatment in order to adapt the dosage of AZA or 6-MP from the start. Some 
remarks have to be made, however. First, when analysing the TPMT genotype in a large cohort of patients with 
severe myelotoxocity under AZA or 6-MP, it was found that only a minority of them had intermediate (17%) or 
low-metabolizing (10%) genotypes.30 This important study indicates that the majority of the bone marrow 
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suppressions under AZA or 6-MP in IBD are not linked to TPMT genotype and that a normal, high 
metabolization profile in a patient does not supplant the need for the monitoring of white blood cells and 
platelets. Second, TPMT activity may vary over time, and measurement at the beginning of the treatment does 
not guarantee the level of activity over the following months or years. Third, at the doses used in IBD the risk of 
early severe myelosuppression essentially exists for TPMT-deficient homozygotes, who represent only 0.3% of 
the population. Hence, when analysing published data on myelotoxicity of AZA or 6-MP, it appears that even in 
the case of TPMT deficiency a severe myelosuppression does not usually occur within I week of treatment13,30 
and can thus be disclosed adequately in the large majority of cases by weekly blood tests during the first month 
of treatment. Furthermore, a homozygote TPMT deficiency has probably no longer to be considered as an 
absolute contraindication for AZA or 6-MP treatment because these patients can be treated safely by adjusting 
the dosage to obtain the lowest effective levels of 6-TGN (Figure I, no. 11 and no. I2).31 This situation is actually 
close to the direct treatment with 6-TG (Figure I, no. 3), which has been advocated by some authors in cases of 
intolerance to AZA and 6-MP32 or high TPMT activity (Figure I, no. 5) which may be associated with relative 
resistance to AZA or 6-MP due to low 6-TGN production (Figure I, no. II and no. 12).33 
Early phase and chronic treatment 
Once treatment with thioguanine derivatives has been initiated there is a double goal to pursue: achieve efficacy 
and check for safety, mainly to avoid myelosuppression and hepatotoxicity. For safety, systematic blood cell 
count and liver function tests must be performed weekly during the first month and then monthly or at least 
every 2 months. As mentioned above, normal TPMT activity or genotyping does not supplant the need for 
regular surveillance of blood cell count. The strategy for achieving optimal efficacy is still controversial. Some 
authors advocate a standard dose with adjustment in non-responders, while others suggest a systematic target 
level of active metabolite, 6-TGN (Figure I, no. 11 and no. 12) or even the monitoring of more complex 
metabolites. 
Adjustment of dose 
Until a few years ago it was accepted that a patient non-responding to 1.5 mg/kg/day of 6-MPor 2-2.5 mg/kg/day 
of AZA should be treated with other drugs. A first pilot study then suggested that an increase in AZA dosage 
beyond 2.5 mg/kg (up to 3-3.5 mg/kg/day) could induce a response in two-thirds of the patients.34 This was done 
under the control of a white blood cell count, provided there was not already a leukopenia. Instead of adjusting 
dosage according to white blood cell count, some authors suggest monitoring metabolites, mainly 6-TGN 
(Figure I, no. 11 and no. 12) and 6-MMP (Figure I, no. 15). 
Monitoring of AZA and 6-MP metabolites 
Several recent studies have analysed correlations between the levels of AZA/6-MP metabolites and the efficacy 
or toxicity of these drugs. A significant positive correlation was documented by some authors between the level 
of erythrocyte 6-TGN (Figure I, no. 11 and no. 12) and clinical response.19,35 A cut-off level of 235 or 250 
pmol/8 × 108 red blood cells was even proposed. However, this correlation was not confirmed by others, 
including the largest study on the topic.36,37 One explanation for this absence of correlation could be that the 
mechanism of action of AZA and 6-MP is more complex and depends also on other metabolites, including 
MeTIMP (Figure I, no. 16) that may inhibit de novo purine synthesis.21 Even in studies in which a positive 
correlation was found between erythrocyte 6-TGN and clinical response, a significant number of patients already 
responded while 6-TGN was below the cut-off level. Obviously these patients do not need an increased dosage 
of AZA or 6-MP. Even if a systematic target level of 6-TGN is not set during treatment, this metabolite may still 
be useful in non-responders, either to check for compliance or to increase the dosage under a control that is more 
specific than simply looking at the white blood cell count.36 A correlation was also documented between 6-MMP 
(Figure I, no. 15) levels and some side-effects, particularly hepatotoxicity.19,20 In some patients non-responding 
to AZA/6-MP and having particularly high TPMT (Figure I, no. 5) activity, an increased dose of AZA/6-MP 
resulted in minor clinical benefit, minor increase in 6-TGN but a significant increase in 6-MMP and dose-
dependent hepatotoxicity.20 It was therefore suggested that these patients, non-responding at standard doses and 
having high 6-MMP levels, should be treated with other drugs or even shifted to 6-TG (Figure I, no. 3). 
Intolerance and inefficacy 
Some problems of tolerance and efficacy cannot be solved by dose adjustment through monitoring of 
metabolites. These situations include allergic-type reactions and drug resistance despite dosage adjustment. In 
some of these situations, a shift from AZA to 6-MP or even 6-TG may be attempted, while some authors have 
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tried to modulate TPMT activity. 
Shift from AZA to 6-MP or 6-TG 
Some side-effects with AZA may be due to the nitro-imidazole metabolite (Figure I, no. 13), released to give 6-
MP. Therefore, in some cases of intolerance to AZA, mainly digestive intolerance (apart from pancreatitis), 
arthralgia, malaise or rash, a treatment with 6-MP may be well tolerated in 50% of cases.38 As we have 
mentioned, hepatotoxicity may be linked to high 6-MMP levels (Figure I, no. 15). In this situation, a treatment 
with 6-TG has been suggested and seems effective and well tolerated.32 A shift to 6-TG has also been proposed 
when AZA or 6-MP are ineffective due to low levels of 6-TGN (Figure I, no. 11 and no. 12) being achieved.33 
However, the data on safety and efficacy of 6-TG in these situations are still preliminary. It must be mentioned 
that the levels of 6-TGN (Figure I, no. 11 and no. 12) achieved under 6-TG treatment are much higher than with 
AZA and 6-MP, and that some concerns exist due to reports of an up to ninefold increased risk of secondary 
malignancy in TPMT heterozygous children treated with thiopurines for remission maintenance in acute 
lymphoblastic leukaemia.39 
Modulation of TPMT activity 
A relative decrease in TPMT activity (Figure I, no. 5) may favour the HGPRT (Figure I, no. 6) pathway and 
therefore increase the production of active metabolites (6-TGN, Figure I, no. 11 and no. 12). Sulphasalazine and 
mesalamine may inhibit TPMT activity (Figure I, no. 19).18 Sulphasalazine treatment was introduced in a small 
number of patients, non-responding to 6-MP, who had high levels of 6-MMP (Figure I, no. 15) and a relatively 
low level of 6-TGN (Figure I, no. 11 and no. 12)20; however, this was not useful in terms of clinical efficacy or 
even in the profile of metabolites. Other ways of TPMT modulation should be explored. 
When to stop AZA/6-MP treatment 
Stopping AZA/6-MP treatment is associated with a high relapse rate. A retrospective study, however, showed 
that the risk of relapse was lower in patients who had been in remission on AZA/6-MP for a longer period of 
time. The risk seemed similar in patients stopping or carrying on with the drug when it was stopped beyond 4 
years of induced remission.4 This was recently re-assessed in a prospective placebo-controlled study.40 Patients 
were followed up for 18 months after randomization in the AZA or placebo group. The relapse rate was 21% in 
the placebo group versus 8% in the AZA group, and the statistical analysis showed that these results were not 
equivalent. These results do not confirm previous retrospective data and indicate that the patient still benefits 
from AZA treatment even after 4 years of remission. Interestingly, a persistent elevated level of C-reactive 
protein under AZA treatment was associated with a higher risk of relapse after stopping treatment. 
SUMMARY 
Thioguanine derivatives, mainly AZA and 6-MP, are major drugs in the treatment of chronic active, steroid-
dependent and infliximab-treated patients. They are effective in two-thirds of the patients and are well tolerated 
over the long term. Over the last 10 years, progress has been made in understanding the metabolism of 
thioguanine derivatives and its implication in clinical practice. New tools and strategies are proposed to try and 
improve both the efficacy and safety of these drugs. TPMT genotyping or activity measurement may be helpful 
before starting the treatment to disclose patients at risk of severe myelosuppression. This has not been 
prospectively validated, however, and these procedures do not supplant the need for regular blood test 
surveillance during the treatment. Starting the treatment directly with the optimal dosage (2-2.5 mg/kg/day for 
AZA and 1-1.5 mg/kg/day for 6-MP) probably accelerates the onset of action. No evidence exists to recommend 
a systematic monitoring of AZA/6-MP metabolites, mainly 6-TGN and 6-MMP, but these measurements can 
help in non-responders to check for compliance and decide on increases in dosage or changes in 
immunosuppressor. In some cases of intolerance to AZA, 6-MP can be tried and, if intolerance exists to both of 
these drugs, 6-TG may be helpful. The risk of relapse when the treatment is stopped decreases with the duration 
of induced remission, but patients still benefit from the drug beyond 4 years of treatment. 
Practice points 
• the usefulness of TPMT genotyping and/or activity measurement before starting treatment remains 
controversial 
• starting treatment with the optimal theoretical dose of AZA (2-2.5 mg/kg) or 6-MP (1-1.5 mg/kg) probably 
accelerates the onset of action 
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• in patients non-responding to a standard dose of AZA/6-MP, dosage can be increased under the control of the 
white blood cell count or erythrocyte 6-TGN concentration                  
• counts of white cells and platelets, as well as liver function tests, must be performed regularly in every patient 
treated with AZA/6-MP 
• some patients intolerant to AZA may tolerate 6-MP, and the majority of the patients intolerant to 6-MP can 
tolerate 6-TG 
•  treatment with AZA/6-MP in IBD should be carried on beyond 4 years as long as it is well tolerated and there 
is no good reason to stop 
Research agenda 
• the interest in, and cost-effectiveness of, a systematic TPMT evaluation before treatment must be prospectively 
evaluated 
• a prospective comparison of AZA and 6-MP tolerance and efficacy would be useful 
• the interest in, and need for, an intravenous loading dose with AZA has still to be further evaluated 
• interest in, and cost-effectiveness of, systematic monitoring with 6-TGN and 6-MMP to improve AZA/6-MP 
treatment must be prospectively evaluated 
• the usefulness of 6-TGN measurement in patients in whom AZA/6-MP dosage is increased beyond standard 
doses must be prospectively compared to the simple white blood cell count 
• safety, efficacy and optimal dosage of 6-TG in IBD must be evaluated in controlled trials 
• attempts at modulating TPMT activity may be relevant to IBD treatment and must be evaluated 
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